Kamada (KMDA) Other Non Operating Income (2012 - 2026)
Kamada's (KMDA) quarterly Other Non Operating Income came in at $90000.0 in Q1 2026, up 178.95% on a YoY basis from $32264.2 in Q1 2025, and up 107.61% quarter-over-quarter from -$1.2 million in Q4 2025.
Powered by 
Analysis
Kamada (KMDA) Other Non Operating Income (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Other Non Operating Income for 15 consecutive years, with $90000.0 the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income rose 178.95% year-over-year to $90000.0; the trailing twelve-month figure through Mar 2026 stood at -$430000.0 (down 106.54% YoY), and the FY2025 full-year result was $2.8 million, down 58.82% from the prior year.
- Other Non Operating Income climbed to $90000.0 in Q1 2026 per KMDA's latest filing, from -$1.2 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $6.7 million in Q4 2024 and bottomed at -$2.2 million in Q4 2023.
- Historically, Other Non Operating Income has averaged $156058.8 across 5 years, with a median of -$71000.0 in 2024.
- The sharpest annual moves came in 2023 and 2025: Other Non Operating Income slumped 4262.96% in 2023, then soared 2920.83% in 2025.
- Over 5 years, Other Non Operating Income stood at $54000.0 in 2022, then plunged by 4262.96% to -$2.2 million in 2023, then soared by 398.31% to $6.7 million in 2024, then sank by 117.64% to -$1.2 million in 2025, then jumped by 107.61% to $90000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $90000.0, -$1.2 million, and -$14000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.77 Bn | 197.79 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.13 Bn | 177.95 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.56 Bn | 56.38 Bn | 1.37 Bn |
| 6 | Moderna | 54.38 Bn | 49.24 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.44 Bn | 31.13 Bn | 992.69 Mn |
| 8 | Biogen | 31.17 Bn | 29.89 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.12 Bn | 30.12 Bn | 1.16 Mn |
| 10 | Kamada | 473.28 Mn | 403.14 Mn | 22.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 90,000.00 |
| Dec 31, 2025 | -1.18 Mn |
| Sep 30, 2025 | -14,000.00 |
| Jun 30, 2025 | 677,000.00 |
| Mar 31, 2025 | -114,000.00 |
| Dec 31, 2024 | 6.71 Mn |
| Sep 30, 2024 | 11,000.00 |
| Jun 30, 2024 | -24,000.00 |
| Mar 31, 2024 | -71,000.00 |
| Dec 31, 2023 | -2.25 Mn |
| Sep 30, 2023 | -157,000.00 |
| Jun 30, 2023 | -88,000.00 |
| Mar 31, 2023 | -156,000.00 |
| Dec 31, 2022 | 54,000.00 |
| Sep 30, 2022 | -46,000.00 |
| Jun 30, 2022 | -676,000.00 |
| Mar 31, 2022 | -108,000.00 |
| Dec 31, 2021 | -25,000.00 |
| Sep 30, 2021 | 68,000.00 |
| Jun 30, 2021 | 30,000.00 |